[
  {
    "ts": null,
    "headline": "The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week",
    "summary": "UnitedHealth  shares took a nosedive Thursday after slashing its annual outlook.  The healthcare conglomerate posted quarterly earnings that fell short of Wall Street’s expectations and substantially downgraded its projected results for 2025.  UnitedHealth—parent of the largest U.S. health insurer—cited higher-than-expected medical costs in its Medicare business, an issue that has affected the entire industry over the past year but had previously not been as significant at UnitedHealth.",
    "url": "https://finnhub.io/api/news?id=c246b08b629c872f71eae9b7afedd3c08c9f67aaa80272c0664841510a8b6314",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745010120,
      "headline": "The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week",
      "id": 133969837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "UnitedHealth  shares took a nosedive Thursday after slashing its annual outlook.  The healthcare conglomerate posted quarterly earnings that fell short of Wall Street’s expectations and substantially downgraded its projected results for 2025.  UnitedHealth—parent of the largest U.S. health insurer—cited higher-than-expected medical costs in its Medicare business, an issue that has affected the entire industry over the past year but had previously not been as significant at UnitedHealth.",
      "url": "https://finnhub.io/api/news?id=c246b08b629c872f71eae9b7afedd3c08c9f67aaa80272c0664841510a8b6314"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows",
    "summary": "The company was first out with the new generation of diabetes and weight-loss treatments known as GLP1 drugs.",
    "url": "https://finnhub.io/api/news?id=8c7bcc8131194971f9cffc7153fb3e0053fee530ce35fbf44663742cf24c3dc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745004000,
      "headline": "Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows",
      "id": 133969838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company was first out with the new generation of diabetes and weight-loss treatments known as GLP1 drugs.",
      "url": "https://finnhub.io/api/news?id=8c7bcc8131194971f9cffc7153fb3e0053fee530ce35fbf44663742cf24c3dc4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery",
    "summary": "Eli Lilly (NYSE:LLY) experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to enhance therapeutic antibody development, while positive results from their Phase 3 trial for Orforglipron highlight potential new treatments for type 2 diabetes. These innovative steps likely bolstered investor confidence despite the overall flat market performance during the same period. With...",
    "url": "https://finnhub.io/api/news?id=edf6f8ef766a6fe7e4040df61629de37bd69dc14c7f31af201145aa28128e0a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744997162,
      "headline": "Eli Lilly (NYSE:LLY) Advances Diabetes Treatment And Partners With BigHat On Antibody Discovery",
      "id": 133969839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) experienced a 16% price increase last week, potentially benefiting from two major developments. The company's collaboration with BigHat Biosciences utilizes advanced technology to enhance therapeutic antibody development, while positive results from their Phase 3 trial for Orforglipron highlight potential new treatments for type 2 diabetes. These innovative steps likely bolstered investor confidence despite the overall flat market performance during the same period. With...",
      "url": "https://finnhub.io/api/news?id=edf6f8ef766a6fe7e4040df61629de37bd69dc14c7f31af201145aa28128e0a9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly promises to make new weight-loss pill in the U.S.",
    "summary": "Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to move production inside the country’s borders.",
    "url": "https://finnhub.io/api/news?id=d98848eecc48ea45dbfc189c61dfa20fde1aea5c150ff24746500808e7240388",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744996440,
      "headline": "Eli Lilly promises to make new weight-loss pill in the U.S.",
      "id": 133969840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to move production inside the country’s borders.",
      "url": "https://finnhub.io/api/news?id=d98848eecc48ea45dbfc189c61dfa20fde1aea5c150ff24746500808e7240388"
    }
  },
  {
    "ts": null,
    "headline": "H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data",
    "summary": "H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate,",
    "url": "https://finnhub.io/api/news?id=8def3f47e8b7d13f3f7109b0b4a553dd1b31747d399f7bee7eb9812c0d08565a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744991711,
      "headline": "H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data",
      "id": 133969841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate,",
      "url": "https://finnhub.io/api/news?id=8def3f47e8b7d13f3f7109b0b4a553dd1b31747d399f7bee7eb9812c0d08565a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing",
    "summary": "Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.",
    "url": "https://finnhub.io/api/news?id=6f295e3646202ed10fce63427c1828a561c9e9eae969174b6f8d03174c7eaa8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744991160,
      "headline": "Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing",
      "id": 133969842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.",
      "url": "https://finnhub.io/api/news?id=6f295e3646202ed10fce63427c1828a561c9e9eae969174b6f8d03174c7eaa8e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly jumps as results from weight-loss pill study rival competitor’s",
    "summary": "Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno",
    "url": "https://finnhub.io/api/news?id=26cc8e678c237028980847127155b9466b4948e4415bce2ee42708062fc3a2c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744989913,
      "headline": "Eli Lilly jumps as results from weight-loss pill study rival competitor’s",
      "id": 133969843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno",
      "url": "https://finnhub.io/api/news?id=26cc8e678c237028980847127155b9466b4948e4415bce2ee42708062fc3a2c2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and BigHat Biosciences ink AI antibody discovery deal",
    "summary": "The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships.",
    "url": "https://finnhub.io/api/news?id=ab283b8b3f46e19928a706f102f4acf7ca3284c82e377d292da0bd5f55a18d0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744989376,
      "headline": "Eli Lilly and BigHat Biosciences ink AI antibody discovery deal",
      "id": 133969844,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships.",
      "url": "https://finnhub.io/api/news?id=ab283b8b3f46e19928a706f102f4acf7ca3284c82e377d292da0bd5f55a18d0f"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Netflix Earnings Crush Views After Weekly Market Losses. Palantir, MercadoLibre Setting Up.",
    "summary": "Dow Jones Futures: Netflix Earnings Crush Views After Weekly Market Losses. Palantir, MercadoLibre Setting Up.",
    "url": "https://finnhub.io/api/news?id=16d99394d26fd1454d168f8f59093875bba8b6368b081ae574e8ebc9dc821050",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744987564,
      "headline": "Dow Jones Futures: Netflix Earnings Crush Views After Weekly Market Losses. Palantir, MercadoLibre Setting Up.",
      "id": 134052599,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Dow Jones Futures: Netflix Earnings Crush Views After Weekly Market Losses. Palantir, MercadoLibre Setting Up.",
      "url": "https://finnhub.io/api/news?id=16d99394d26fd1454d168f8f59093875bba8b6368b081ae574e8ebc9dc821050"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): One of the Best Long Term Stocks to Buy According to Billionaires",
    "summary": "We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long term stocks. Dividend-paying stocks have traditionally been seen as a solid foundation for investment portfolios, offering steady […]",
    "url": "https://finnhub.io/api/news?id=3076b6e2c48fc22442903d0cc505a1431792e505c8b53215697dd04fecbc998f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744986589,
      "headline": "Eli Lilly and Company (LLY): One of the Best Long Term Stocks to Buy According to Billionaires",
      "id": 133969845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best long term stocks. Dividend-paying stocks have traditionally been seen as a solid foundation for investment portfolios, offering steady […]",
      "url": "https://finnhub.io/api/news?id=3076b6e2c48fc22442903d0cc505a1431792e505c8b53215697dd04fecbc998f"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics",
    "summary": "JPMorgan analyst Hardik Parikh says Eli Lilly’s (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the ext",
    "url": "https://finnhub.io/api/news?id=1f2eb9bcfa67404442ec840edbad61462a8ca44e6f561a93c1ce61413ad0d55f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744986368,
      "headline": "JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics",
      "id": 133969846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "JPMorgan analyst Hardik Parikh says Eli Lilly’s (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the ext",
      "url": "https://finnhub.io/api/news?id=1f2eb9bcfa67404442ec840edbad61462a8ca44e6f561a93c1ce61413ad0d55f"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Swoon Could Hit Some P&C Insurers Harder Than Others",
    "summary": "Stock Market Swoon Could Hit Some P&C Insurers Harder Than Others",
    "url": "https://finnhub.io/api/news?id=1b0d030265192bc608852dcf016566ffe1c274e846e153fc95f6f4ae105f203a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744984980,
      "headline": "Stock Market Swoon Could Hit Some P&C Insurers Harder Than Others",
      "id": 133966423,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1b0d030265192bc608852dcf016566ffe1c274e846e153fc95f6f4ae105f203a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch",
    "summary": "By Denny Jacob Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The...",
    "url": "https://finnhub.io/api/news?id=8135788f38bd48e4f6b8b98f08f387a20b40863508ad5c686d16ec3aa8fcfc56",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744977488,
      "headline": "Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch",
      "id": 133965995,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Denny Jacob Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The...",
      "url": "https://finnhub.io/api/news?id=8135788f38bd48e4f6b8b98f08f387a20b40863508ad5c686d16ec3aa8fcfc56"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly releases topline data for new oral GLP-1",
    "summary": "Eli Lilly and Company has announced positive topline results for the first oral small molecule glucagon-like peptide-1 receptor agonist, taken without food and water restrictions, to successfully...",
    "url": "https://finnhub.io/api/news?id=0e3557af23de513125e80534267d9609a2e6d747709c769e56248e72679d1505",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744959666,
      "headline": "Eli Lilly releases topline data for new oral GLP-1",
      "id": 133963922,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company has announced positive topline results for the first oral small molecule glucagon-like peptide-1 receptor agonist, taken without food and water restrictions, to successfully...",
      "url": "https://finnhub.io/api/news?id=0e3557af23de513125e80534267d9609a2e6d747709c769e56248e72679d1505"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly and Company (LLY) is Skyrocketing?",
    "summary": "We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading week mixed, with two of the major […]",
    "url": "https://finnhub.io/api/news?id=332bdaa7230d2f40d34b8baa4d1bfc23d7c713647d950f1d0518ffe7e6e2c606",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744957912,
      "headline": "Why Eli Lilly and Company (LLY) is Skyrocketing?",
      "id": 133964506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading week mixed, with two of the major […]",
      "url": "https://finnhub.io/api/news?id=332bdaa7230d2f40d34b8baa4d1bfc23d7c713647d950f1d0518ffe7e6e2c606"
    }
  },
  {
    "ts": null,
    "headline": "89bio: A Buy With Strong Market Opportunity In MASH And SHTG",
    "summary": "89bio: A Buy With Strong Market Opportunity In MASH And SHTG",
    "url": "https://finnhub.io/api/news?id=3590d192cd323fee18a1fd9e1c3babb1d387a7e6623b3e6ca0c2fcef9c2da980",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744951570,
      "headline": "89bio: A Buy With Strong Market Opportunity In MASH And SHTG",
      "id": 133963179,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3590d192cd323fee18a1fd9e1c3babb1d387a7e6623b3e6ca0c2fcef9c2da980"
    }
  }
]